Skip to main content

Table 2 Prognostic significance of clinicopathologic factors and influence on long-term recurrence/metastasis-free survival in entire cohort and MBC subset

From: Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified

Covariates Univariate analysis Multivariate analysis cox regression of survival
MBC Entire cohort MBC Entire cohort
  Χ 2 P Χ 2 P RR (95% CI) P RR (95% CI) P
Age ≤50 years <0.001 0.998 0.47 0.490 1.32 (0.38 to 4.56) 0.666 1.39 (0.91 to 2.12) 0.129
Tumor size ≥2 cm 0.62 0.432 25.35 <0.001 0.42 (0.08 to 2.31) 0.320 2.71 (1.39 to 5.28) 0.003
Node-positive 2.34 0.127 99.36 <0.001 0.74 (0.16 to 3.53) 0.710 2.40 (1.42 to 4.07) 0.001
Higher TNM stage 4.53 0.031 95.60 <0.001 7.84 (0.76 to 80.54) 0.083 2.19 (1.33 to 3.62) 0.002
ER-positive 0.14 0.706 0.57 0.184 1.15 (0.34 to 3.98) 0.817 0.92 (0.58 to 1.44) 0.697
PR-positive 0.04 0.847 0.38 0.103 1.06 (0.28 to 3.92) 0.936 0.80 (0.52 to 1.24) 0.321
HER2/neu-positive 1.70 0.193 8.29 0.004 1.31 (0.37 to 4.69) 0.677 1.31 (0.86 to 2.00) 0.204
Chemotherapy 1.02 0.314 0.89 0.345 0.37 (0.07 to 2.01) 0.251 0.60 (0.30 to 1.20) 0.151
Radiotherapy 7.75 0.005 96.42 <0.001 0.13 (0.03 to 0.71) 0.015 1.81 (1.22 to 2.92) 0.015
Hormonotherapy 0.13 0.722 18.70 <0.001 0.50 (0.13 to 1.93) 0.317 0.69 (0.43 to 1.01) 0.122
  1. CI, confidence interval; ER, estrogen receptor; HER2/neu, human epidermal growth factor receptor 2; MBC, medullary breast carcinoma; PR, progesterone receptor; RR, relative risk.